Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17341 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Fynn Gurski and 10 co-authors. Institution: Experimental Neurology, Department of Neurology, University of Giessen, Giessen, Germany. Major MEDLINE topics: Encephalomyelitis, Autoimmune, Experimental, Mice, Inbred C57BL, Remyelination, Multiple Sclerosis. Cited 4 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background and Purpose FGF, VEGFR‐2 and CSF1R signalling pathways play a key role in the pathogenesis of multiple sclerosis (MS). Selective inhibition of FGFR by infigratinib in MOG 35‐55 ‐induced experimental autoimmune encephalomyelitis (EAE) prevented severe first clinical episodes by 40%; inflammation and neurodegeneration were reduced, and remyelination was enhanced. Multi‐kinase inhibition of FGFR1‐3, CSFR and VEGFR‐2 by fexagratinib (formerly known as AZD4547) may be more efficient in reducing inflammation, neurodegeneration and regeneration in the disease model. Experimental Approach Female C57BL/6J mice were treated with fexagratinib (6.25 or 12.5 mg·kg −1 ) orally or placebo over 10 days either from time of EAE induction (prevention experiment) or onset of symptoms (suppression experiment). Effects on inflammation, neurodegeneration and remyelination were assessed at the peak of the disease (Day 18/20 post immunization) and the chronic phase of EAE (Day 41/42). Key Results In the prevention experiment, treatment with 6.25 or 12.5 mg·kg −1 fexagratinib prevented severe first clinical episodes by 66.7% or 84.6% respectively. Mice treated with 12.5 mg·kg −1 fexagratinib hardly showed any symptoms in the chronic phase of EAE. In the suppression experiment, fexagratinib resulted in a long‐lasting reduction of severe symptoms by 91 or 100%. Inflammation and demyelination were reduced, and axonal density, numbers of oligodendrocytes and their precursor cells, and remyelinated axons were increased by both experimental approaches. Conclusion and Implications Multi‐kinase inhibition by fexagratinib in a well‐tolerated dose of 1 mg·kg −1 in humans may be a promising approach to reduce inflammation and neurodegeneration, to slow down disease progression and support remyelination in patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Experimental Neurology, Department of Neurology, University of Giessen, Giessen, Germany.
- Institute of Neuropathology, University Medical Centre Göttingen, Göttingen, Germany.
- Institute for Anatomy and Cell Biology, University of Giessen, Giessen, Germany.
- Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany.
ORCID profiles: Kian Shirvanchi, Vinothkumar Rajendran
Cite
APA
Gurski, F., Shirvanchi, K., Rajendran, V., Rajendran, R., Megalofonou, F. F., Böttiger, G., Stadelmann, C., Bhushan, S., Ergün, S., Karnati, S., & Berghoff, M. (2025). Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis. British Journal of Pharmacology. https://doi.org/10.1111/bph.17341
Vancouver
Gurski F, Shirvanchi K, Rajendran V, Rajendran R, Megalofonou FF, Böttiger G, et al. Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis. British Journal of Pharmacology. 2025. doi:10.1111/bph.17341
BibTeX
@article{Gurski2025,
author = {Gurski, Fynn and Shirvanchi, Kian and Rajendran, Vinothkumar and Rajendran, Ranjithkumar and Megalofonou, Fevronia-Foivi and Böttiger, Gregor and Stadelmann, Christine and Bhushan, Sudhanshu and Ergün, Süleyman and Karnati, Srikanth and Berghoff, Martin},
title = {Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17341}
}
EUVIMED